Cagrilintide: The Amylin-Analogue Research Behind CagriSema

No — cagrilintide is the individual molecule; CagriSema is Novo Nordisk's development name for the fixed-dose combination of cagrilintide 2.4 mg with semaglutide 2.4 mg, co-administered once weekly. Search demand for 'cagrilintide' is frequently really a search for CagriSema, because that is where almost all of the later-stage trial activity — and nearly all of the headline results — actually sit.^[2][4]

The scientific logic for pairing the two molecules is that amylin and GLP-1 signalling reach appetite-control circuits through different, complementary routes. In mice, cagrilintide's weight-lowering effect has been traced to amylin receptors AMY1 and AMY3 acting on brainstem regions — the dorsal vagal complex and lateral parabrachial nucleus — that are distinct from where GLP-1 receptor agonists like semaglutide act most strongly. A 2024 review of amylin analogues described the resulting effect of combining the two mechanisms as additive on appetite reduction, though it also noted a caveat: gastrointestinal side effects were more frequent with cagrilintide than with the older amylin analogue pramlintide.^[6][7]

The only trial to test cagrilintide as a true standalone therapy against placebo was a phase 2, dose-finding study (Lau et al., 2021) run at 57 sites across ten countries. It enrolled 706 adults with overweight or obesity who did not have diabetes, randomly assigning them to one of five once-weekly cagrilintide doses (0.3, 0.6, 1.2, 2.4 or 4.5 mg), to once-daily liraglutide 3.0 mg as an active comparator (99 participants), or to placebo (101 participants), over a 26-week treatment period.^[1]

By week 26, mean weight loss ranged from 6.0% at the lowest cagrilintide dose to 10.8% at the highest (4.5 mg), versus 3.0% with placebo — a dose-dependent, statistically significant separation at every dose tested (p<0.001). The top cagrilintide dose also outperformed liraglutide 3.0 mg (10.8% versus 9.0%, p=0.03). Discontinuation occurred in about 10% of participants across groups, mostly because of adverse events; gastrointestinal complaints — principally nausea — were more common with cagrilintide (reported in 41-63% of participants, dose-dependent) than with placebo (32%).^[1]

Read narrowly, this is a single 26-week phase 2 trial in a non-diabetic population: real evidence of a dose-response relationship on bodyweight, but not a long-term or phase 3 dataset for cagrilintide used alone. Every larger trial that followed moved to studying cagrilintide alongside semaglutide instead of repeating the monotherapy design.^[1]

The first co-administration data came from a phase 1b trial (Enebo et al., 2021) in 96 healthy adults with overweight or obesity, which paired ascending cagrilintide doses with semaglutide 2.4 mg over a 16-week escalation. By week 20, cagrilintide 2.4 mg plus semaglutide produced 17.1% mean weight loss versus 9.8% with placebo plus semaglutide alone — the earliest signal that adding cagrilintide meaningfully increased weight loss beyond semaglutide by itself. The trial's primary purpose was safety and pharmacokinetics rather than efficacy, and it found the combination generally well tolerated, with gastrointestinal disorders accounting for 37% of the adverse events reported.^[2]

A phase 2 trial in people with type 2 diabetes (Frias et al., 2023) gave the cleanest head-to-head comparison: 92 participants were randomly assigned to CagriSema, semaglutide alone, or cagrilintide alone, all escalated to 2.4 mg weekly, for 32 weeks. Bodyweight fell by 15.6% with CagriSema, 8.1% with cagrilintide alone, and 5.1% with semaglutide alone — CagriSema was significantly greater than both single-molecule arms (p<0.0001). HbA1c improved most with CagriSema (-2.2 percentage points) and was not significantly different from semaglutide alone (p=0.075), but was significantly better than cagrilintide alone (p<0.0001).^[3]

Novo Nordisk's phase 3 REDEFINE programme is the largest cagrilintide-related dataset published so far. REDEFINE 1 (Garvey et al., 2025, New England Journal of Medicine) enrolled 3,417 adults with overweight or obesity but without diabetes, randomised to CagriSema, semaglutide alone, cagrilintide alone, or placebo, alongside lifestyle intervention, for 68 weeks. CagriSema produced an estimated mean weight change of -20.4% versus -3.0% with placebo (treatment difference -17.3 percentage points, p<0.001), with participants significantly more likely to reach 5%, 20%, 25% and 30% weight-loss thresholds than those on placebo.^[4]

REDEFINE 2 (Davies et al., 2025, New England Journal of Medicine) tested the same CagriSema dose in 1,206 adults who had both overweight/obesity and type 2 diabetes, across 12 countries, again over 68 weeks. Bodyweight fell by 13.7% with CagriSema versus 3.4% with placebo (p<0.001), and 73.5% of the CagriSema group reached an HbA1c of 6.5% or lower, versus 15.9% on placebo. Gastrointestinal adverse events were reported by 72.5% of the CagriSema group and 34.4% of the placebo group in this trial, mostly described as transient and mild to moderate.^[5]

A 2026 meta-analysis pooling four randomised trials (5,425 participants in total) confirmed the broad pattern — clinically meaningful weight loss with both cagrilintide monotherapy and CagriSema, plus improvements in waist circumference, blood pressure and, for the combination, HbA1c — while explicitly flagging substantial heterogeneity between trials and adverse-event rates that were modestly but consistently higher on active treatment. Its conclusion was that larger, longer trials are still needed to confirm durability.^[8]

The adverse-event pattern is consistent across every cagrilintide trial published so far, whether the molecule was tested alone or with semaglutide: gastrointestinal symptoms — nausea, vomiting, diarrhoea and constipation — are by far the most frequently reported adverse events, generally described by trial authors as transient and mild to moderate in severity. Rates rose with cagrilintide dose in the monotherapy trial (gastrointestinal events in 41-63% of participants across doses, versus 32% on placebo) and rose further with the combination in the phase 3 programme (79.6% with CagriSema versus 39.9% with placebo in REDEFINE 1; 72.5% versus 34.4% in REDEFINE 2).^[1][4][5]

What the published trials do not yet cover is long-term safety beyond 68 weeks, or safety in broader real-world populations outside a clinical-trial protocol. Discontinuation because of adverse events has been a consistent minority outcome (around 10% in the phase 2 monotherapy trial) rather than a dominant one, but the evidence base remains bounded by trial duration and by populations selected for specific BMI and, in some trials, diabetes-status criteria.^[1]

A 2025 study in EBioMedicine examined exactly which amylin receptors cagrilintide needs to lower bodyweight. Working with mice genetically engineered to lack the receptor activity-modifying proteins RAMP1 and RAMP3 — and so lacking functional AMY1 and AMY3 receptors — the researchers found that normal mice lost weight on cagrilintide (-3.4 g over three weeks) while the knockout mice's response was substantially blunted, directly demonstrating that cagrilintide needs AMY1 and AMY3 receptor signalling to produce its weight-loss effect in this model.^[6]

The same study found that cagrilintide activated neurons (marked by cFos expression) in the dorsal vagal complex and lateral parabrachial nucleus — hindbrain regions involved in appetite and satiety signalling — in normal mice, and that this activation dropped by 57% in the receptor-knockout animals. That is a coherent, mechanistically specific finding, but it is mouse data from a single laboratory study, not confirmed human neuroscience: it explains a plausible pathway, not a proven one in people.^[6]

No. Cagrilintide has not been approved by the FDA and has no EMA marketing authorisation, whether as a standalone molecule or as the CagriSema combination. Every result described in this guide comes from registered clinical trials, not from a marketed product. REDEFINE 1, the largest of those trials, is registered on ClinicalTrials.gov as a phase 3 study, listed as active but no longer recruiting, sponsored by Novo Nordisk.^[9]

That matters for how to read every figure in this guide: a 20.4% or 13.7% mean weight change is a trial result reported under a specific randomised protocol, with a specific comparator, duration and population — not a claim about what happens with unsupervised, non-clinical use of the compound. None of the trials cited here studied cagrilintide, or CagriSema, outside a monitored clinical-trial setting.^[1][4][5]

Peptyds supplies semaglutide as a lyophilised research peptide for in-vitro laboratory work only, with batch documentation described on the quality page. It does not supply cagrilintide. Nothing on this page is an offer to sell cagrilintide, and nothing here should be read as instruction for personal or human use of any compound — cagrilintide remains an investigational molecule studied only inside registered clinical trials.

Readers arriving here from semaglutide, retatrutide or CagriSema searches will usually find better answers in the articles this guide is built to sit alongside: the GLP-1 overview compares the receptor-agonist class as a whole, and the semaglutide product page describes what Peptyds actually supplies, including its own batch and purity documentation.